Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Accumulated Depreciation (2017 - 2025)

Historic Accumulated Depreciation for Aclaris Therapeutics (ACRS) over the last 9 years, with Q3 2025 value amounting to $5.0 million.

  • Aclaris Therapeutics' Accumulated Depreciation rose 649.57% to $5.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.0 million, marking a year-over-year increase of 649.57%. This contributed to the annual value of $4.8 million for FY2024, which is 1544.93% up from last year.
  • According to the latest figures from Q3 2025, Aclaris Therapeutics' Accumulated Depreciation is $5.0 million, which was up 649.57% from $5.0 million recorded in Q2 2025.
  • In the past 5 years, Aclaris Therapeutics' Accumulated Depreciation registered a high of $5.0 million during Q2 2025, and its lowest value of $2.9 million during Q1 2021.
  • Moreover, its 5-year median value for Accumulated Depreciation was $4.2 million (2023), whereas its average is $4.1 million.
  • As far as peak fluctuations go, Aclaris Therapeutics' Accumulated Depreciation skyrocketed by 2935.57% in 2021, and later skyrocketed by 165.07% in 2024.
  • Aclaris Therapeutics' Accumulated Depreciation (Quarter) stood at $3.4 million in 2021, then increased by 18.92% to $4.0 million in 2022, then increased by 3.15% to $4.2 million in 2023, then rose by 15.45% to $4.8 million in 2024, then grew by 3.73% to $5.0 million in 2025.
  • Its Accumulated Depreciation was $5.0 million in Q3 2025, compared to $5.0 million in Q2 2025 and $4.9 million in Q1 2025.